ModifiedUnitedHealthcarePolicy CS079ID.A

Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Idaho Only)

Medical policy governing coverage and medical necessity determinations for minimally invasive endoscopic and laparoscopic procedures to treat gastric and esophageal conditions for members in Idaho, including Idaho Medicaid Plus.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for Gastric and Esophageal Diseases (for Idaho Only)

Policy CodePolicy CS079ID.A

Change TypeNew Medical Policy

Effective DateJune 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization for listed procedure codes when submitting for members in Idaho, ensuring documentation of prior conservative therapy and relevant objective testing as applicable.

SourceLink

POLICY UPDATE CHANGES

New Medical Policy

06/01/2025policy effective date

83-91%POEM clinical success (reported)

2,468Stretta meta-analysis sample

7Applicable procedure codes

87%post-MSA PPI withdrawal rate

Coverage Criteria and Evidence Summaries

POEM — covered indications

Covered when ALL of the following are met

POEM for achalasia or diffuse esophageal spasm: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with Achalasia or Diffuse Esophageal Spasm.

Supported by systematic reviews and comparative series summarized in the policy (see evidence sections).

Unproven / Not medically necessary

Not covered / Unproven indications

G-POEM for gastroparesis: Gastric per oral endoscopic myotomy (G-POEM) is unproven and not medically necessary for the treatment of Gastroparesis.

Policy cites insufficient high-quality evidence and need for larger randomized trials.

Endoscopic therapies, injection or implantation techniques, and LINX for GERD: Endoscopic therapies (including Stretta, TIF/EsophyX/MUSE/GERDx, endoscopic plication/suturing), injection or implantation/bulking techniques, and the LINX Reflux Management System are unproven and not medically necessary for treating GERD due to insufficient evidence of long-term efficacy.

Includes radiofrequency (Stretta), endoscopic plication (EsophyX/TIF, GERDx, MUSE), polymer/bulking injections, and implantable devices per policy descriptions.

EndoFLIP (FLIP) for diagnosis of achalasia: Functional lumen imaging probe (EndoFLIP) technology is unproven and not medically necessary for diagnosing Achalasia.

Policy states evidence is insufficient to support routine diagnostic use.

GERDx endoluminal therapy: Endoluminal therapy with GERDx is investigational, unproven, and not medically necessary for treating GERD as it has not received FDA approval.

Policy explicitly lists GERDx as investigational.

Esophageal POEM evidence

Evidence summary for esophageal POEM (achalasia)

POEM vs LHM evidence: Systematic review/meta-analysis (Marano et al.) of 11 studies (total 486 patients) comparing POEM and laparoscopic Heller myotomy found non‑statistically significant differences in Eckardt score favoring POEM but noted high heterogeneity, no randomized trials, publication bias, and follow-up limited to ≤1 year.

Authors recommended randomized long-term trials to better define comparative outcomes.

Z-POEM evidence

Evidence summary for Zenker's diverticulum (Z-POEM and septotomy)

Z-POEM comparative findings: Multiple observational studies and multicenter retrospective cohorts (including a 245‑patient study) report comparable initial clinical success for Z‑POEM versus flexible and rigid septotomy but with variable recurrence and adverse event rates; overall evidence is limited by retrospective designs, heterogeneity, small samples, and short or inconsistent follow-up.

Policy concludes insufficient high-quality evidence and calls for prospective, longer-term comparative studies.

G-POEM evidence

Evidence summary for G-POEM (gastroparesis)

G-POEM outcomes: Systematic reviews, cohort series, and a sham‑controlled RCT demonstrate symptom and gastric emptying improvements in many patients with refractory gastroparesis, with variable reported clinical success across studies; the RCT (Martinek et al., n=41) showed greater treatment success versus sham at 6 months but was limited by small sample size and notable serious adverse events.

Policy states insufficient quality and generalizability of evidence to consider G‑POEM medically necessary broadly; larger and longer trials needed.

Stretta evidence

Evidence summary for Stretta (radiofrequency for GERD)

Stretta evidence: Systematic reviews and randomized and observational studies produce mixed results: some sham‑controlled RCTs showed no significant benefit over sham, while other meta‑analyses and case series report improvements in symptoms, quality of life, and reduced PPI use; overall evidence quality is low to moderate and long‑term comparative effectiveness versus fundoplication remains uncertain.

Policy highlights need for well‑designed longer‑term RCTs to clarify efficacy.

Evidence summary / implied applicability

Summary of evidence and typical inclusion features from studies (not formal coverage criteria):

Typical study inclusion features: Adult patients with chronic GERD symptoms, objective evidence of pathologic acid exposure or esophagitis, and persistent symptoms despite PPI therapy.

Derived from multiple device and trial inclusion criteria.

Reported beneficial outcomes: Reported improvements include ≥50% reduction in GERD‑HRQL, reduction or cessation of daily PPI use, and decreased esophageal acid exposure or DeMeester scores; magnitudes vary by device and study.≥50% GERD‑HRQL reduction used as study success in many trials

See device‑specific evidence summaries.

Limitations affecting coverage decisions: Most positive evidence arises from observational cohorts or small RCTs with short‑to‑moderate follow‑up; durability beyond 3–5 years is uncertain for many endoscopic devices.

These limitations influence determinations of medical necessity for many procedures.

Typical trial-based candidacy

Evidence from randomized trials and prospective series generally enrolled patients meeting these characteristics:

MSA/TIF typical enrollment criteria: Patients with chronic GERD symptoms despite PPI therapy; objective evidence of pathologic acid reflux on pH testing or abnormal esophageal acid exposure; hiatal hernia size typically ≤ 2–3 cm; absence of advanced esophagitis or Barrett's (trial‑specific); and documented preoperative diagnostic testing (EGD, pH monitoring, manometry).hiatal hernia <= 2-3 cm; abnormal pH/DeMeester per trial

Derived from inclusion criteria of multiple randomized trials and prospective studies (e.g., TEMPO, Bell et al., Louie et al.).

Durability and risk tradeoffs

Outcomes and durability considerations relevant to coverage decisions include:

Durability/Objective control concerns: Some TIF studies demonstrated symptomatic improvement but lacked sustained objective reflux control (low pH normalization rates) with resumption of PPIs over time; conversely, MSA (LINX) reports substantial short‑term normalization of acid exposure but carries risks of dysphagia and device removal/erosion.pH normalization variable; PPI resumption rates up to 61% in some TIF cohorts

Objective follow‑up testing is advised when long‑term control is required.

MSA (LINX) — candidate considerations

Covered when supported by clinical evidence and guideline recommendations:

MSA candidate criteria (study/guideline-derived): Patients with objective evidence of pathologic GERD (e.g., esophageal pH testing) AND persistent symptoms despite medical therapy or desire to avoid long‑term PPI, AND anatomy suitable for device placement (absence of large hiatal hernia or advanced Barrett's in many study series).as documented in individual studies and ACG guidance

Derived from trial inclusion criteria and ACG/SAGES recommendations; prior authorization should document objective testing and anatomic suitability.

EndoFLIP / FLIP — evidence-based stance

Coverage stance for EndoFLIP:

EndoFLIP: Evidence is insufficient to support routine use of EndoFLIP for diagnosing or managing esophageal and gastric disorders; EndoFLIP may be considered investigational or adjunctive pending further high‑quality studies.insufficient evidence

Multiple systematic reviews and technology assessments found low‑quality and inconsistent evidence; routine diagnostic or standalone use is not established.

Zenker's peroral endoscopic myotomy (Z-POEM) currently lacks sufficient high-quality evidence to establish its long-term safety and effectiveness. The policy notes that published clinical literature does not include large, well-designed studies with standardized postprocedure protocols and that long-term monitoring and confirmatory evidence are insufficient to support routine coverage of Z-POEM for Zenker's diverticulum.

Gastric POEM (G-POEM) for gastroparesis and the Stretta radiofrequency procedure for GERD are considered to have insufficient high-quality evidence to broadly conclude long-term safety and efficacy. The document highlights heterogeneous patient populations, predominance of single-center and retrospective studies, small samples, and short follow-up in the literature as key limitations.

Some endoscopic therapies for GERD (for example, endoluminal plication, suturing, and polymer injection techniques) have shown short-term symptomatic benefit in select series but demonstrated progressive loss of response over time in longer follow-up. The policy specifically cites case series reporting symptomatic improvement up to 12 months with increasing nonresponse out to 60 months and concludes there is a lack of durable objective improvement (manometry/pH) in several studies.

Magnetic sphincter augmentation (MSA / LINX) has promising short-term outcomes in many reports but the policy states long-term safety and effectiveness remain uncertain. Limitations include short follow-up in numerous studies, methodological bias, and variable reporting of adverse events such as postoperative dysphagia, need for dilation, device removal, and rare erosion events.

Several studies and assessments excluded or cautioned use of MSA for patients with large hiatal hernias or Barrett's esophagus. The policy therefore advises that MSA be considered for appropriately selected patients and notes that many trial populations excluded those with large hiatal hernias or advanced Barrett's, limiting generalizability to those groups.

FDA approvals and device clearances are presented for informational purposes only. The policy explicitly states that FDA approval alone is not a basis for coverage and that regulatory clearance does not imply automatic coverage under member benefit plans.

This Medical Policy is informational and is not medical advice. Coverage determinations are governed by applicable federal, state, or contractual benefit requirements, which take precedence if they differ from this policy.

The policy lists multiple procedures and techniques considered investigational, unproven, or not medically necessary for the stated indications. These include G-POEM for gastroparesis; endoscopic therapies for GERD (including Stretta, endoscopic plication/suturing, EsophyX/TIF, GERDx, MUSE); injection or implantation/bulking agents (for example, Plexiglas, Durasphere, Enteryx); the LINX Reflux Management System when used outside evidence-based settings; and EndoFLIP (FLIP) for routine diagnostic use in achalasia.

Procedures without robust randomized comparative evidence or adequate long-term follow-up are considered investigational when performed outside controlled trial settings. The policy emphasizes that many positive reports are single-center, retrospective, or lack randomization and that such limitations reduce confidence in long-term benefit when procedures are used broadly.

Specific techniques cited as having insufficient evidence include certain endoscopic plication/suturing approaches and injection/implantation methods (eg, EndoCinch, polymer injections, Plexiglas, Durasphere). The policy concludes that available studies are limited by small sizes, lack of control groups, inconsistent definitions of success, and inadequate long-term objective data.

Endoscopic injection and implantation techniques (for example, Plexiglas, Durasphere, Enteryx, Gatekeeper, EndoCinch) are described as having insufficient evidence to establish safety and effectiveness for GERD. Systematic review data cited in the policy support that long-term benefit remains unproven for these bulking and implantation approaches.

Use of EndoFLIP (FLIP) is not supported for routine diagnostic assessment, procedure guidance, or post-procedure evaluation. The policy summarizes systematic reviews and technology assessments that found the evidence insufficient to conclude improved health outcomes and therefore considers EndoFLIP unsupported for routine clinical use outside investigational or adjunctive contexts.

Applicable Codes, Device Approvals, and Related Metrics

Procedure / CPT Codes (reference)CPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed
43289	Unlisted laparoscopy procedure, esophagus
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM])
43499	Unlisted procedure, esophagus
43999	Unlisted procedure, stomach

FDA-cleared / approved endoluminal and related devices (informational)mixed

Stretta System	Radiofrequency thermal ablation system for treatment of GERD — FDA approval April 2000
Bard EndoCinch Endoscopic Suturing System	Endoscopic suturing system for GERD — FDA approval January 2001; updated version approved September 2007
NDO Surgical Endoscopic Plication System	Endoscopic suturing/plication system for GERD — FDA approval September 2007
EsophyX / EsophyX2	Endoluminal fundoplication system; original EsophyX cleared September 2007; EsophyX2 cleared November 2009 via 510(k) as substantially equivalent
LINX Reflux Management System	Magnetic sphincter augmentation (MSA) system — FDA premarket approval (PMA) March 2012, PMA P100049

FDA PMA / 510(k) identifiers (reference)mixed

Stretta	Approval documentation: K103017 (Stretta System)
Bard EndoCinch	510(k)/approval documentation referenced in K071651 (EndoCinch)
NDO Plication	510(k)/approval documentation referenced in K071651 (NDO Surgical Endoscopic Plication System)
EsophyX2	Cleared via 510(k) November 2009 as substantially equivalent to predicate devices (original EsophyX cleared September 2007)
LINX	PMA P100049 (LINX Reflux Management System)

Prior Authorization, Documentation, and Decision Support

Prior Authorization

Authorization applies to listed procedure codes (Idaho)

Prior authorization applies to the procedure and diagnosis codes listed in the Applicable Codes section for services performed in Idaho (including Idaho Medicaid Plus). Providers should obtain authorization before scheduling interventions to avoid claim denials.

Affected codes: CPT 43210, 43257, 43284, 43289, 43497, 43499, 43999 (see Applicable Codes list)
Applies only to services in Idaho (this policy)

Prior Authorization

Prior authorization considerations — evidence and regulatory context

Prior authorization decisions should consider the strength and limits of available evidence: randomized trials, comparative studies, long-term follow-up, and device-specific safety signals (e.g., erosion rates for MSA, complication reports for TIF/MUSE). FDA clearance/approval is informational only and does not by itself determine coverage. Documentation supporting medical necessity and prior conservative therapy should be submitted.

Clinical Background

Background: GERD, achalasia, diffuse esophageal spasm, and gastroparesis are distinct clinical conditions with differing pathophysiology and treatment options. Conservative management (eg, dietary measures, proton pump inhibitors) is effective for many GERD patients, while achalasia and spastic esophageal disorders may be treated with POEM, laparoscopic Heller myotomy, or pneumatic dilation; gastroparesis management includes dietary, pharmacologic, and procedural options. POEM is identified in the policy as proven and medically necessary for achalasia and diffuse esophageal spasm when supported by the cited evidence.

Terms and Definitions

Achalasia definition

DefinitionA primary esophageal motor disorder characterized by degeneration of the myenteric plexus resulting in impaired relaxation of the esophagogastric junction and loss of organized peristalsis.

Source attributionAmerican Society of Gastrointestinal Endoscopy (ASGE) phrasing used in policy definitions

Clinical implicationDiagnosis typically requires manometry as gold standard (context in policy evidence sections)

Diffuse Esophageal Spasm definition

DefinitionA rare esophageal motility disorder characterized by simultaneous, uncoordinated, or rapidly propagated contractions of normal amplitude accompanied by dysphagia.

Clinical features

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for Gastric and Esophageal Diseases (for Idaho Only)

Policy CodePolicy CS079ID.A

Change TypeNew Medical Policy

Effective DateJune 1, 2025

Next Review DateN/A

SourceLink

On This Page

Consider trial quality, follow-up duration, and applicability to the member
FDA approval/clearance is informational — coverage depends on benefit terms

Prior Authorization

Prior authorization suggested for TIF with hiatal hernia repair

When TIF is performed concurrently with hiatal hernia repair, prior authorization is suggested due to limited and low-quality evidence evaluating combined procedures. Provide documentation of rationale and objective testing results.

Include pre-op endoscopy findings and hiatal hernia size
Supply evidence of refractory symptoms despite optimized therapy

Documentation Required

MSA candidate documentation

For magnetic sphincter augmentation (MSA/LINX) candidates, submit objective preoperative documentation including validated symptom scores, esophageal pH testing results, hiatal hernia size, esophagogastroduodenoscopy findings, and prior medical therapy trial details.

Required pre-op tests: ambulatory pH or DeMeester score, EGD, manometry when indicated
Document GERD-HRQL or other validated symptom scores and PPI use history

Denial Risk

Evidence limitations may trigger denial

Evidence gaps, short follow-up, small sample sizes, lack of randomization or comparison groups, and inconsistent objective outcomes may lead to coverage denial for unproven indications (for example: endoscopic therapies for GERD other than those with explicit positive evidence).

POEM: evidence limitations for non-achalasia indications may lead to declined coverage
Endoscopic therapies for GERD (broadly) deemed unproven in Coverage Rationale

Denial Risk

Objective outcome failure risk — document realistic expectations

Prior authorization reviewers will consider objective outcome failure risks: for example, TIF may not normalize pH in all patients and some will resume PPI therapy; disclose prior objective testing and expectations for pH normalization and symptom control.

Report prior ambulatory pH results and prior response to PPIs
Document expectations and counseling about potential need to resume PPI therapy

Denial Risk

Complication-related review risk — device erosion/removal and serious AEs

Complication risks (e.g., device erosion or removal with MSA, perforation with TIF/MUSE, postprocedural dysphagia) should be documented and reviewed; prior authorization may trigger additional scrutiny for patients at higher risk of device-related complications.

Report prior foregut surgeries, anatomy, and factors increasing erosion/dysphagia risk
For MSA, note documented erosion/removal rates and monitoring plan

Note

Coverage decisions must reference federal, state, or contractual requirements

Coverage decisions must reference applicable federal, state, and contractual benefit requirements — when a conflict exists, the governing requirement (federal/state/contract) determines coverage. This policy assists interpretation but does not override plan-specific terms.

Verify Idaho-specific plan riders and Medicaid Plus rules before authorizing
In event of conflict, federal/state/contractual requirements govern

Documentation Required

Document device indication and patient selection referencing FDA summaries

When documenting device-based interventions (e.g., LINX, MSA, EsophyX, MUSE), clearly state the device indication, cite relevant FDA summaries where applicable, and provide rationale for patient selection referencing clinical criteria and objective testing.

Include device model/name and PMA/510(k) as applicable (e.g., LINX PMA P100049)
Cite objective testing that supports device use (pH, EGD, manometry)

Step Therapy

Conservative therapy precedent for GERD — require prior conservative therapy

Conservative management must be tried and documented prior to consideration of most minimally invasive GERD interventions. Document OTC measures, H2 blockers, and a trial of optimized PPI therapy (dose and duration).

Document duration and adherence to PPI therapy (typical requirement: > 8 weeks and/or chronic use)
Detail lifestyle and OTC therapies attempted

Prior Authorization

Require optimized medical therapy prior to endoscopic/surgical intervention

Prior to endoscopic or surgical interventions, optimized medical therapy should be documented — including a PPI trial at standard or twice-daily dosing when indicated. For many endoscopic interventions, objective failure of optimized therapy is expected before approval.

Record PPI dose, duration, and response
For endoscopic interventions, note failure or intolerance of optimized medical management

Note

Therapy sequencing — document prior steps

Therapy sequencing should be explicit in prior authorization submissions: conservative measures → optimized medical therapy → consideration of endoscopic or minimally invasive surgical options based on anatomy and objective testing. Step therapy policies may be payer-specific.

Sequence: lifestyle/OTC → PPI (optimized) → diagnostic testing → endoscopic/surgical options
Document prior steps taken and timing

Step Therapy

Step therapy not specified — follow payer-specific rules

This policy does not define a single mandatory step-therapy pathway; follow payer- and contract-specific step therapy rules where applicable. If step therapy is enforced by the benefit, prior authorization requirements will reflect those contractual rules.

If payer-specific step therapy applies, include evidence of completion or exception requests in the submission
When step therapy is not specified here, use the member's plan rules

Symptoms commonly include dysphagia and chest pain; recognized as a spastic motility disorder

Diagnostic noteManometry is the typical diagnostic modality; referenced in policy background

Gastroesophageal Reflux Disease (GERD) definition

DefinitionCondition in which the lower esophageal sphincter relaxes too often or weakens, allowing stomach acid to reflux into the esophagus.

Clinical relevanceGERD often responds to PPI therapy but a substantial minority remain symptomatic, motivating consideration of procedural options

Outcome measuresSymptoms, GERD‑HRQL, pH monitoring/DeMeester scores used in studies

Gastroparesis definition

DefinitionChronic disorder characterized by delayed gastric emptying in the absence of mechanical obstruction.

Etiologic heterogeneityIncludes diabetic, idiopathic, medication‑induced, and postsurgical causes as noted in evidence summaries

Clinical consequenceValidated symptom scores and gastric emptying studies (GES) commonly used in eligibility and outcome reporting

G-POEM definition

DefinitionGastric peroral endoscopic myotomy — endoscopic pyloromyotomy technique intended to treat refractory gastroparesis.

Evidence stancePolicy states insufficient high‑quality evidence to support safety and long‑term efficacy

Study considerationsClinical trials and cohort series report variable outcomes; further RCTs and long‑term data needed

Z-POEM definition

DefinitionZenker's peroral endoscopic myotomy — endoscopic technique to treat Zenker's diverticulum by performing myotomy of the septum.

Evidence notePolicy indicates insufficient quality evidence and recommends need for comparative, long‑term studies

Clinical outcomesExisting series report technical feasibility and symptomatic improvement but are limited by small, retrospective designs

Stretta definition

DefinitionEndoscopic delivery of radiofrequency (RF) energy to the gastroesophageal junction (Stretta system) intended to improve GERD symptoms and reduce PPI dependence.

Evidence characterizationSystematic reviews and RCTs report mixed results; overall evidence quality limited by small studies and short follow‑up

Clinical impact reportedMeta-analyses report improvements in quality‑of‑life scores and reduced PPI use in some cohorts but uncertainty persists versus surgical fundoplication

TIF definition

DefinitionTransoral incisionless fundoplication (TIF/EsophyX) — an endoscopic technique to create a fundoplication‑like valve at the gastroesophageal junction to reduce reflux.

Indications/limitsUsed for symptomatic chronic GERD in patients who respond to pharmacologic therapy; many trials enrolled patients with hiatal hernia ≤2 cm

Outcomes assessedSymptom scores (GERD‑HRQL), pH monitoring/DeMeester scores, and PPI discontinuation are primary endpoints in studies

Stretta (radiofrequency energy) definition duplicate

Definition (duplicate)Endoscopic radiofrequency energy applied to the gastroesophageal junction (Stretta) aiming to improve GERD symptoms and reduce acid exposure.

Evidence summaryPolicy reiterates mixed evidence and need for well‑designed long‑term trials

Regulatory/contextConsidered an endoscopic modality evaluated across RCTs and observational cohorts

Troublesome regurgitation definition

DefinitionTroublesome regurgitation — patient‑reported regurgitation symptoms often used as a primary outcome in randomized trials comparing TF/TIF or MSA to PPIs.

MeasurementAssessed using validated questionnaires (eg, GERD‑HRQL) and used to compare procedural versus medical therapy outcomes

Trial contextHunter et al. trial used troublesome regurgitation elimination at 6 months as a key endpoint

Clinical success (MSA studies) definition

DefinitionClinical success in some MSA cohorts defined as ≥50% improvement in total GERD‑HRQL score and discontinuation of PPI medication.

Study applicationUsed as a predefined success criterion in LINX/MSA prospective and post‑approval studies (eg, Louie et al.)

DocumentationRequires validated GERD‑HRQL measurement and medication usage data pre‑ and post‑procedure

MSA / LINX definition

DefinitionMagnetic sphincter augmentation (MSA/LINX) — an implantable magnetic ring placed laparoscopically around the lower esophageal sphincter to augment sphincter function and reduce reflux.

Regulatory noteLINX Reflux Management System received FDA premarket approval (PMA P100049) — informational in the policy

Clinical considerationsTrials required objective pH testing and enrolled patients with pathologic acid exposure; risks include postoperative dysphagia and rare erosion/device removal

EndoFLIP definition

DefinitionEndoFLIP (Functional Lumen Imaging Probe) — an impedance planimetry system that measures distensibility index (DI) and cross‑sectional area to assess esophagogastric junction and sphincter properties as an adjunct to other diagnostics.

Regulatory statusEndoFLIP received 510(k) clearance and is indicated as an adjunctive tool to other diagnostic methods (policy cites FDA 510k information)

Evidence stancePolicy states evidence is insufficient for routine diagnostic use and utility remains to be defined; may be adjunctive or investigational

EsophyX2 indications (definition)

Definition / device indicationEsophyX2 — device indicated for transoral tissue approximation and full‑thickness plication/ligation to treat symptomatic chronic GERD and reduce hiatal hernia <2 cm.

Regulatory referenceFDA documentation cited for device intended uses and limitations (policy references FDA materials)

Common trial enrollmentMany EsophyX/TIF studies enrolled patients with small hiatal hernias (≤2 cm) and required objective evaluation pre‑procedure

LINX Reflux Management System (definition)

DefinitionLINX Reflux Management System — the commercial magnetic sphincter augmentation implant system cleared via FDA PMA (P100049) for management of GERD.

Regulatory detailPMA number P100049 cited in policy FDA section as informational reference

Clinical contextUsed in patients with documented pathologic acid reflux and anatomical suitability; studies report improvements but note dysphagia and device‑related risks

EndoFLIP (impedance planimetry) (definition duplicate)

Definition (duplicate)EndoFLIP — an impedance planimetry system indicated to measure pressure and dimensions in the esophagus, pylorus, and anal sphincters as an adjunctive diagnostic tool.

Evidence summaryPolicy reiterates insufficient evidence for routine diagnostic application; utility yet to be defined

Operational detailMeasures distensibility index (DI) and cross‑sectional area during volumetric distension per described protocols

Magnetic sphincter augmentation (MSA) — supplemental definition

Supplemental definitionMagnetic sphincter augmentation (MSA) — implantable device to augment the lower esophageal sphincter; associated literature reports efficacy but highlights postoperative dysphagia and rare erosion/removal events.

Reported outcomesStudies report substantial proportions off PPI and normalization of acid exposure in many patients but note device removal rates and dysphagia incidence

Selection considerationsTrials commonly required objective pH testing and anatomic suitability (eg, absence of large hiatal hernia)

Endoscopic GERD therapies — broad definition

Definition (broad)Endoscopic GERD therapies — encompasses Stretta (radiofrequency), transoral incisionless fundoplication (TIF/EsophyX, MUSE), endoscopic plication (GERDx, Plicator), and injection/implantation bulking agents as endoscopic approaches to treat GERD symptoms and reduce PPI dependence.

Evidence characterizationPolicy summarizes mixed and generally low‑to‑moderate quality evidence across modalities with variable durability and calls for higher‑quality comparative trials

Regulatory/contextSome devices have FDA 510(k) clearance or PMA (eg, EndoFLIP 510k; MUSE 510k; LINX PMA) but FDA status alone is informational and does not imply coverage